Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 8/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843836 | 1.00 | ADRA2A (0.44) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1844707 | 0.83 | ADRA2A (0.51) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1844705 | 0.83 | ADRA2A (0.51) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL3786576 | 0.79 | GAA (0.46) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1845858 | 0.79 | GAA (0.46) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1844519 | 0.78 | ADRA2A (0.53) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1844522 | 0.78 | ADRA2A (0.53) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2625552 | 0.72 | — | — | |
| SCHEMBL15087184 | 0.71 | ADRA2A (0.64) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL9021052 | 0.71 | ADRB2 (0.44) | ADRA2CADRB2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858653-B2 | 2-imidazoles | HOFFMAN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-7858653-B2 | 2-imidazoles | HOFFMAN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080146634-A1 | 2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | ADRA2A 6/4885ADRA2C 27/4885ADRA1D 20/4885 |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | ADRA2A 6/4885ADRA2C 34/4885ADRA1D 29/4885 |
| US-20080146634-A1 | 2-IMIDAZOLES | ABL1, H1-2, IPO4 | ADRA2A 84/4885ADRA2C 13/4885ADRA1D 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.